# Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

> **NCT04005170** · PHASE2 · COMPLETED · sponsor: **Mian XI** · enrollment: 42 (actual)

## Conditions studied

- Unresectable Esophageal Cancer

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Paclitaxel/Cisplatin
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT04005170
- **Lead sponsor:** Mian XI
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-25
- **Primary completion:** 2020-12-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2022-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04005170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04005170, "Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04005170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*